Candel Therapeutics reports phase 3 prostate cancer biomarker data
The company said the data from its completed aglatimagene besadenovec trial showed sustained immune remodeling more than two years after treatment versus radiotherapy alone.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.